MAP2K1 and ovarian carcinoma: By targeting mitogen-activated protein kinase 1 (MAPK1)/growth factor receptor bound protein 2 (GRB2), MiR-378a-3p makes ovarian cancer cells more sensitive to cisplatin [25].